Key Points:
1.The licensing program is expected to bring in an additional 6 billion rubles to the budget annually.
2.Of the total, 3 billion rubles will be specifically allocated for the treatment of COPD patients.
3.Chronic Obstructive Pulmonary Disease (COPD) has become the second leading cause of death among individuals aged 35-45.
According to the Russian media outlet Tehnowar, the Russian Democratic Forces have proposed using funds obtained from the introduction of retail licenses for nicotine products to support the fight against Chronic Obstructive Pulmonary Disease (COPD).
The assistant vice president of the association made the above remarks at the "Shemashko Russian Medical Forum."
This concept involves using funds from the introduction of retail licenses for nicotine products to support the fight against chronic obstructive pulmonary disease.
According to the organization's initial estimates, the implementation of a licensing system is expected to generate over 60 billion rubles ($7.4 billion) in revenue annually. Of this amount, 30 billion rubles ($3.7 billion) would be sufficient to provide treatment for all COPD patients in Russia. At least 7% of the Russian population is affected by this disease. Additionally, there is a growing trend of lung cancer among younger individuals, with lung cancer ranking second as the leading cause of respiratory disease-related deaths in patients aged 35-45.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
